These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30535008)

  • 41. Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy - early promise but more data needed. Authors' reply.
    Bouguen G; Siproudhis L
    Aliment Pharmacol Ther; 2019 Mar; 49(6):817-818. PubMed ID: 30811643
    [No Abstract]   [Full Text] [Related]  

  • 42. [Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect].
    Zhou Y; Chen Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1833-8. PubMed ID: 24369257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-infliximab antibodies: How to compare old and new data?
    Imbrechts M; Van Stappen T; Compernolle G; Tops S; Gils A
    J Pharm Biomed Anal; 2020 Jan; 177():112842. PubMed ID: 31526960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Infliximab in inflammatory bowel diseases--conference summary and suggested guidelines].
    Dotan I; Chowers Y; Rachmilewitz D; Chermesh I; Lavy A; Israeli E; Karban A; Schwaber MJ; Odes S; Eliakim R
    Harefuah; 2006 Nov; 145(11):844-9, 860. PubMed ID: 17183961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
    Gonczi L; Gecse KB; Vegh Z; Kurti Z; Rutka M; Farkas K; Golovics PA; Lovasz BD; Banai J; Bene L; Gasztonyi B; Kristof T; Lakatos L; Miheller P; Nagy F; Palatka K; Papp M; Patai A; Salamon A; Szamosi T; Szepes Z; Toth GT; Vincze A; Szalay B; Molnar T; Lakatos PL
    Inflamm Bowel Dis; 2017 Nov; 23(11):1908-1915. PubMed ID: 28922253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of biologics in the treatment of patients with inflammatory bowel disease.
    Selinger CP; Carbery I; Al-Asiry J
    Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.
    Grossberg LB; Papamichael K; Feuerstein JD; Siegel CA; Ullman TA; Cheifetz AS
    Inflamm Bowel Dis; 2017 Dec; 24(1):191-197. PubMed ID: 29272486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
    Gibson DJ; Ward MG; Rentsch C; Friedman AB; Taylor KM; Sparrow MP; Gibson PR
    Aliment Pharmacol Ther; 2020 Mar; 51(6):612-628. PubMed ID: 31961001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays.
    Silva-Ferreira F; Afonso J; Pinto-Lopes P; Magro F
    Inflamm Bowel Dis; 2016 Sep; 22(9):2289-301. PubMed ID: 27508512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
    Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
    World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
    Franca R; Curci D; Lucafò M; Decorti G; Stocco G
    Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
    [No Abstract]   [Full Text] [Related]  

  • 53. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.
    Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG
    J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease.
    Greener T; Kabakchiev B; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2018 Jul; 24(8):1808-1814. PubMed ID: 29697810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
    Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
    Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Lo Pumo S; Brunacci M; De Bortoli N; Jain A; Tolone S; Savarino E
    Dig Liver Dis; 2018 May; 50(5):452-456. PubMed ID: 29274766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients.
    Taks M; Pijls PA; Derijks LJ; Ten Broeke R; Grouls RJ; Curvers J; Gilissen LP
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):169-173. PubMed ID: 27749780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.
    Koller T; Galambosova M; Filakovska S; Kubincova M; Hlavaty T; Toth J; Krajcovicova A; Payer J
    World J Gastroenterol; 2017 Jun; 23(22):4102-4111. PubMed ID: 28652663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring.
    Barlow NL; Mohammed P; Berg JD
    Ann Clin Biochem; 2016 Jul; 53(Pt 4):477-84. PubMed ID: 26290514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic potential of infliximab in inflammatory bowel disease.
    Hurd LB; Lichtenstein GR
    Gastroenterol Nurs; 1999; 22(5):199-208. PubMed ID: 10776108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.